BayBio Presentations

CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. A list of grants and loans awarded to date may be seen here: http://www.cirm.ca.gov/for-researchers/researchfunding. 

Speaker

Elona Baum
General Counsel

Session 3
Emerging Issues in the Conduct of Global Clinical Trials
2:45PM – 4:00PM
Join this dynamic panel as we discuss the issues associated with the conduct of clinical trials outside the US, in particular, in emerging jurisdictions. Topics include: Challenges in managing a global trial; whether and how to use CROs, risks and rewards of conducting trials in China, India, Russia and other emerging jurisdictions; recruitment, cost and time to site initiation; special challenges for virtual or smaller biotechs, including management of CMO and CROs and addressing pressures of financing sources.

Stacie S. Switzer
Assistant General Counsel, Takeda Pharmaceuticals North America, Inc.

10:00am – 10:20am: The Myelin Repair Foundation (MRF)
The Myelin Repair Foundation (MRF) is a Silicon Valley-based, non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for multiple sclerosis. MRF’s Accelerated Research Collaboration™ (ARC™) model is designed to optimize the entire process of medical research, drug development and the delivery of patient treatments. To date, MRF-supported research has identified more than 150 potential myelin repair treatment targets and the discovery of 24 new research tools to advance research for potential multiple sclerosis therapeutics. In order to advance basic science to commercialization, the MRF Translational Medicine Center led by MRF scientists with extensive biopharma experience moving therapeutics into clinical trials, is a laboratory facility dedicated to the evaluation of promising myelin research as potential multiple sclerosis candidates for MRF biopharma partners. The goal of the MRF is to provide a clear industry pathway from bench to bedside by leveraging its position as a non-partisan, non-profit organization to shorten the time to market for new medicines for patients who can’t afford to wait.
Speaker
Jay Tung, PhD
Vice President of Drug Discovery

12:15pm – 12:25pm: Melanoma Research Alliance (MRA)
The Melanoma Research Alliance (MRA) is a public charity formed under the auspices of the Milken Institute, with the generous founding support of Debra and Leon Black. It supports an international, cross-disciplinary group of biomedical researchers possessing clinical and scientific expertise to explore, identify and pursue innovative solutions to critical research questions, leading to better treatments and a cure for melanoma patients. In its first four year, MRA has awarded over $30 million to 73 research programs to make transforming advances in the prevention, diagnosis, staging, and treatment of melanoma, including research in biological causes of carcinogenesis, skin screening, biomarkers, imaging, immunotherapy, molecularly targeted therapy, and combination therapy. MRA has become the largest private funder of melanoma research in the United States.
Speaker
Wendy Selig
President and CEO

4:40PM – 5:00PM: Alzheimer’s Association
The Alzheimer’s Association is the leading, global voluntary health organization in Alzheimer’s care and support, and the largest private, nonprofit funder of Alzheimer’s research. Our vision: A world without Alzheimer’s disease. Our mission: To eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. http://www.alz.org
Speaker
Jay A. Thompson
Senior Associate Director, Corporate Initiatives
Alzheimer’s Association

Clinical Development
Session 2
Ten Tips to Accelerate Clinical Trials and Do Them Well
11:45AM – 1:00PM
Richard Malcolm, Ph.D.
CEO, Acurian, Inc.

Clinical Development
Track 2
Thursday, March 8, 2012
Session 1
Patient Advocacy: The Key to the Next Evolution of Clinical Development
10:00AM – 11:15AM
Craig Martin
CEO, Feinstein Kean Healthcare

Session 2
Patient Access to Developmental Drugs
11:30AM – 12:45PM
Julia Jenkins
Director of Public & Government Relations, The EveryLife Foundation for Rare Diseases
Rare Disease Legislative Advocates

Track 3
Friday, March 9, 2012
Session 1
Taking Matters into Their Own Hands:
The Role of Patients in Drug Development
9:45AM – 11:00AM
Robert Fisher, M.D., Ph.D.
Scientific Advisory Board Member, The Epilepsy Therapy Project
Professor of Neurology and Director
Stanford Comprehensive Epilepsy Center, Stanford University

The Use of Social Media in Patient Recruitment for Clinical Trials
Larry A. Risen
President
Patient Recruiters International, Inc.

Session 3
Social Media and Life Sciences: Hearing a Patient’s Voice
2:30PM – 3:45PM
Lisa Papworth-Buckland
Director, Consulting & Sales, Sermo

Session 3
Social Media and Life Sciences: Hearing a Patient’s Voice
2:30PM – 3:45PM
Malcolm Bohm
Chief Executive Officer
LiquidGrids Inc.

CALBIO2012 Annual Conference
Track 2; Session 1
Regulatory Risk: How Do We Manage?
Friday, March 9, 2012
9:45AM – 11:00AM
Manisha Deshmukh
Regulatory Affairs
BioMarin Pharmaceutical, Inc.

Coverage and Reimbursement Risks: The Influence of Deficit Reduction and Other Pressures
CALBIO 2012 Conference – March 9, 2012 (11:30-12:45 pm)
Peter G. Milner, M.D., FACC
Founder, Optivia Biotechnology, CV Therapeutics, Inc. and ARYx Therapeutics, Inc.
Former Assistant Professor of Medicine at Washington University

Patient Access to Investigational Drugs

Life Threatening Diseases with Unmet Medical Need (Unsolved!)

Turn Existing Science into Near Term Treatment Options

Role of Patient Advocacy Groups in Accelerating Drug Development

Dr. Diane Stephenson
Associate Director, CAMD

BioSupply Management Alliance | Supplier Management - Mystery or Mastery? An introduction to supplier management

Presenters: 

BayBio2011: Powering Global Innovation

Luncheon Keynote: Gregg H. Alton, Executive Vice President, Corporate and Medical Affairs, Gilead Sciences